EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma

Oxana Yu Kytikova iD, Juliy M Perelman iD, Tatyana P Novgorodtseva, Yulia K Denisenko iD, Viktor P Kolosov, Marina V Antonyuk, Tatyana A Gvozdenko

PPAR Research · 14.01.2020 · 2020 · 1-18

DOI: 10.1155/2020/8906968 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PPAR Research, erschienen am 14.01.2020. Verfasst von Oxana Yu Kytikova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vladivostok Branch of Far Eastern Scientific Centre of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative T…. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education and Science of the Russian Federation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complexity of the pathogenetic mechanisms of the development of chronic inflammation in asthma determines its heterogeneity and insufficient treatment effectiveness. Nuclear transcription factors, which include peroxisome proliferator-activated receptors, that is, PPARs, play an important role in the regulation of initiation and resolution of the inflammatory process. The ability of PPARs to modulate not only lipid homeostasis but also the activity of the inflammatory response makes them an important pathogenetic target in asthma therapy. At present, special attention is focused on natural (polyunsaturated fatty acids (PUFAs), endocannabinoids, and eicosanoids) and synthetic (fibrates, thiazolidinediones) PPAR ligands and the study of signaling mechanisms involved in the implementation of their anti-inflammatory effects in asthma. This review summarizes current views on the structure and function of PPARs, as well as their participation in the pathogenesis of chronic inflammation in asthma. The potential use of PPAR ligands as therapeutic agents for treating asthma is under discussion.

Autor:innen und Institutionen

  • Vladivostok Branch of Far Eastern Scientific Centre of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russia.
  • Far Eastern Scientific Center of Physiology and Pathology of Respiration, Russian Academy of Sciences, Blagoveshchensk, Russia.

ORCID-Profile: Oxana Yu Kytikova, Juliy M Perelman, Yulia K Denisenko

Förderung

  • Ministry of Education and Science of the Russian Federation

Zitieren

APA

Kytikova, O. Y., Perelman, J. M., Novgorodtseva, T. P., Denisenko, Y. K., Kolosov, V. P., Antonyuk, M. V., & Gvozdenko, T. A. (2020). Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma. PPAR Research, 2020, 1-18. https://doi.org/10.1155/2020/8906968

Vancouver

Kytikova OY, Perelman JM, Novgorodtseva TP, Denisenko YK, Kolosov VP, Antonyuk MV, et al. Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma. PPAR Research. 2020;2020:1-18. doi:10.1155/2020/8906968

BibTeX
@article{Kytikova2020,
  author = {Kytikova, Oxana Yu and Perelman, Juliy M and Novgorodtseva, Tatyana P and Denisenko, Yulia K and Kolosov, Viktor P and Antonyuk, Marina V and Gvozdenko, Tatyana A},
  title = {Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma},
  journal = {PPAR Research},
  year = {2020},
  volume = {2020},
  pages = {1--18},
  doi = {10.1155/2020/8906968}
}
Kostenlos starten →